Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Aihara M., Ropo A., Lu F., Kawata H., Iwata A., Odani-Kawabata N., Shams N.
View publication
-
Therapeutic Area
Glaucoma
-
Categories
Clinical development
-
Affiliations
Ophthalmology, University of Tokyo, Tokyo, Japan; Santen Oy, Vantaa, Finland; Santen Inc., Emeryville, CA, United States; Santen Pharmaceutical Co., Ltd, Osaka, Japan